Gemphire Therapeutics Inc. (GEMP) Increased to $10.11 on Jun, 29

June 29, 2018 - By Toni Killen

Gemphire Therapeutics Inc. (NASDAQ:GEMP) trading at $10.11 after increase. The move was reported on Jun, 29 by Barchart.com. The company has $143.89M market cap. At $10.72 PT, the company’s valuation could be $8.63 million more.

Earnings report for Gemphire Therapeutics Inc. (NASDAQ:GEMP) is awaited on August, 13., RTT reports. This year’s EPS analyst estimate is awaited to be $-0.57. That is 22.97 % up compareed to $-0.74 EPS for last year. After $-0.58 EPS report last quarter, Wall Street now sees -1.72 % EPS growth of Gemphire Therapeutics Inc..

For more Gemphire Therapeutics Inc. (NASDAQ:GEMP) news brought out recently go to: Nasdaq.com, Benzinga.com, Benzinga.com, Benzinga.com or Nasdaq.com. The titles are as follows: “Mid-Morning Market Update: Markets Open Higher; Constellation Brands Earnings Miss Estimates” brought out on June 29, 2018, “Benzinga Pro’s 5 Stocks To Watch Today” on June 29, 2018, “5 Stocks Moving In Thursday’s After-Hours Session” with a publish date: June 21, 2018, “42 Biggest Movers From Yesterday” and the last “Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients” with publication date: June 28, 2018.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis .The firm is valued at $143.89 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH.Currently it has negative earnings.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: